News Author: Mark L. Fuerst Publish date: December 12, 2014
Photo courtesy of ASH
SAN FRANCISCO—The oral proteasome inhibitor ixazomib induces high-quality hematologic responses in patients with relapsed/ref...
News Author: Mark L. Fuerst Publish date: December 11, 2014
“It is encouraging to see results in an NHL study that selects a different target than CD20,” said Kristie Blum, MD, of The Ohio State University i...
News Author: Mark L. Fuerst Publish date: December 11, 2014
the 2014 ASH Annual Meeting
SAN FRANCISCO—Combination therapy with ruxolitinib and panobinostat shows signs of efficacy in myelofibrosis (MF), acco...
News Author: Mark L. Fuerst Publish date: November 5, 2014
Credit: Rhoda Baer
NEW YORK—Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent
Hodgk...
News Author: Mark L. Fuerst Publish date: November 5, 2014
NEW YORK—Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients prior to...
News Author: Mark L. Fuerst Publish date: June 23, 2014
©ASCO/Phil McCarten
CHICAGO—The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV) who ...
News Author: Mark L. Fuerst Publish date: June 20, 2014
©ASCO/Phil McCarten
CHICAGO—Elderly males with non-Hodgkin lymphoma (NHL) may require one-third higher doses of rituximab than the current standard...
News Author: Mark L. Fuerst Publish date: June 19, 2014
©ASCO/Phil McCarten
CHICAGO—Patients with chronic myeloid leukemia (CML) are more likely to achieve a deep molecular response if they switch to nil...
News Author: Mark L. Fuerst Publish date: June 13, 2014
©ASCO/Todd Buchanan
CHICAGO—Infusion of autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells appears to have promising anti-tu...
News Author: Mark L. Fuerst Publish date: June 12, 2014
©ASCO/Scott Morgan
CHICAGO—Substituting lenalidomide for thalidomide in the standard treatment of newly diagnosed multiple myeloma (MM) improves qu...
News Author: Mark L. Fuerst Publish date: June 11, 2014
©ASCO/Rodney White CHICAGO—The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as monotherapy...
News Author: Mark L. Fuerst Publish date: June 11, 2011
CHICAGO—Two phase 3 studies demonstrate the effectiveness of the investigational Janus kinase (JAK) inhibitor INC424 (ruxolitinib) in treating patient...
News Author: Mark L. Fuerst Publish date: December 13, 2009
The B-cell receptor is present on both normal B cells and malignant B cells. Signaling through this receptor is necessary for B-cell maturation and...
